EnWave Signs Research Evaluation Agreement with Merck

EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave", or the "Company")
today announced that it has signed a Research Evaluation Agreement with Merck,
through a subsidiary. 


Under the terms of the agreement Merck will conduct a field test to determine
the feasibility of the Radiant Energy Vacuum ("REV") Technology using EnWave's
new multi-vial pilot-scale equipment. In addition, EnWave has granted Merck an
exclusive research license to use the Company's technology and licensed patents
for the duration of the evaluation and an option to obtain an exclusive
commercial worldwide license to EnWave's portfolio. 


"We are very excited to begin a research evaluation program with Merck," said
Dr. Tim Durance, Co-CEO, EnWave Corporation. "This represents further progress
towards our goal of establishing REV as a viable commercial technology in the
pharmaceutical setting."


EnWave's dehydration technology portfolio for pharmaceuticals and biomaterials
includes freezeREV(TM), powderREV(TM) and bioREV(TM); each employing a
combination of microwave energy with a low pressure environment to achieve
rapid, highly controlled dehydration of live or active biological materials
stored in sterile vials or in bulk powder, with the goal of significantly
reducing the process time and cost of dehydration. 


About EnWave 

EnWave Corporation is a Vancouver-based industrial technology company developing
commercial applications for its proprietary Radiant Energy Vacuum (REV)
dehydration technology. In collaboration with an expanding list of multinational
partners, including Nestle, Kellogg's, Grupo Bimbo, Grimmway Farms, Ocean Spray,
Hormel and Bonduelle. EnWave is introducing REV as a new dehydration standard in
the food and biological material sectors: potentially faster than freeze drying,
with better end product quality than air drying or spray drying. 


EnWave currently has six REV platforms: commercial-scale nutraREV(TM) and
MIVAP(TM) are used in the food industry to dry fruits, vegetables, meat, herbs
and seafood quickly, while maintaining high levels of nutrition, taste, texture
and colour. The Company is also developing powderREV(TM) for bulk dehydration of
food cultures, probiotics and fine biochemicals such as enzymes; quantaREV(TM)
for continuous, high-volume low-temperature drying of pastes, gels, liquids, or
particulates; and bioREV(TM) and freezeREV(TM) as new methods to stabilize and
dehydrate biopharmaceuticals such as vaccines and antibodies. More information
about EnWave is available at www.enwave.net.


EnWave Corporation

Dr. Tim Durance, Chairman & Co-CEO

Safe Harbour for Forward-Looking Information Statements: This press release may
contain forward-looking information based on management's expectations,
estimates and projections. All statements that address expectations or
projections about the future, including statements about the Company's strategy
for growth, product development, market position, expected expenditures and
financial results are forward-looking statements. These statements are not a
guarantee of future performance and involve a number of risks, uncertainties and
assumptions. There is no guarantee that the Company's REV technology can or will
improve processes in the target industry; even if the Company's REV technology
can be used as described in this document, there is no guarantee that such use
will result in orders for the Company's REV technology. All figures comparing
REV technologies to freeze drying or other dehydration technologies are provided
as examples of data obtained through the Company's own scientific and testing
programs; each product must be tested individually to determine the benefits of
using REV.
(TSXV:REV)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024